Terrapin Beer Co. Celebrates 20 Years of Iconic Wake-n-Bake Beer with Exciting Wake-n-Bake Off Event in Athens, GA
GlobeNewswire· 2025-01-23 12:00
ATHENS, Ga., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Terrapin Beer Co., a Tilray Beverages craft beer brand under Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is excited to announce the 20th anniversary of its Wake-n-Bake Coffee Oatmeal Imperial Stout seasonal beer and the annual Wake-n-Bake Off event on Sunday, January 26th, 2025, at the Terrapin taproom in Athens, GA. In celebration of its 20th anniversary, guests will have the chance to observe local restaurants competing to craft the finest dish featurin ...
OLD REPUBLIC REPORTS RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2024
Prnewswire· 2025-01-23 12:00
Dollar amounts (other than per share amounts) are presented in millions, except as otherwise indicated. CHICAGO, Jan. 23, 2025 /PRNewswire/ -- Old Republic International Corporation (NYSE: ORI) today reported the following results for the fourth quarter and full year 2024: Fourth quarter net income per diluted share of $0.42, compared to $0.69 last year. Fourth quarter net operating income (net income excluding investment gains or losses) per diluted share of $0.90, compared to $0.69 last year. Consolidate ...
Aduro Clean Technologies Achieves Key Milestone in Pilot Plant Design
GlobeNewswire· 2025-01-23 12:00
Completion of Basic Design for Hydrochemolytic™ Technology Pilot PlantLONDON, Ontario, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, is pleased to announce the successful completion of the Basic Engineering Design phase for its Hydrochemolytic ...
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
GlobeNewswire· 2025-01-23 12:00
Investor webinar scheduled Tuesday, January 28, 2025, at 8:00 AM ESTMIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical t ...
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
GlobeNewswire· 2025-01-23 12:00
CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in an oral presentation at the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marro ...
American Airlines Reports Fourth-Quarter and Full-Year 2024 Financial Results
GlobeNewswire· 2025-01-23 12:00
FORT WORTH, Texas, Jan. 23, 2025 (GLOBE NEWSWIRE) -- American Airlines Group Inc. (NASDAQ: AAL) today reported its fourth-quarter and full-year 2024 financial results, including: Record fourth-quarter revenue of $13.7 billion and record full-year revenue of $54.2 billionFourth-quarter and full-year GAAP net income of $590 million and $846 million, or $0.84 and $1.24 per diluted share, respectively Excluding net special items1, fourth-quarter and full-year net income of $609 million and $1.4 billion, or $0.8 ...
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's Disease
GlobeNewswire News Room· 2025-01-23 12:00
- Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease (AD) - - Robust and dose-dependent reductions of sTREM2 were achieved demonstrating sustained functional target engagement – - Company plans to advance VG-3927 into a Phase 2 trial in the third quarter of 2025; Selects 25mg QD oral as a dose that fully engages desired pharmacology - WATERTOWN, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vigi ...
AleAnna, Inc. To Celebrates Public Listing With NASDAQ Bell-Ringing Ceremony
GlobeNewswire· 2025-01-23 12:00
AleAnna Celebrates Milestone As It Contributes To Europe’s Access To Secure And Sustainable Energy And Leads In The Transition To Low Carbon Energy SolutionsAleAnna utilizes cutting-edge reservoir characterization technologies and possesses over 140,000 acres of 3D seismic data to optimize reservoir performance and unlock Italy's natural gas reserves. AleAnna owns significant holdings spanning over 2.7 million acres, including Italy’s largest onshore natural gas discovery in two decades.AleAnna’s RNG portfo ...
Lithium Argentina Completes Corporate Migration to Switzerland
GlobeNewswire· 2025-01-23 12:00
ZUG, Switzerland, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Lithium Argentina AG (formerly Lithium Americas (Argentina) Corp.) (“Lithium Argentina” or the “Company”) (TSX: LAAC) (NYSE: LAAC) announces that it has completed the previously announced plan to establish corporate domicile in Switzerland from Canada (“Corporate Migration”). As part of the Corporate Migration, the Company has changed its name to Lithium Argentina AG. The Company continues the listing of its common shares on the Toronto Stock Exchange (“TS ...
Valley National Bancorp Reports Fourth Quarter 2024 Results
GlobeNewswire· 2025-01-23 12:00
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Valley National Bancorp (NASDAQ:VLY), the holding company for Valley National Bank, today reported net income for the fourth quarter 2024 of $115.7 million, or $0.20 per diluted common share, as compared to the third quarter 2024 net income of $97.9 million, or $0.18 per diluted common share, and net income of $71.6 million, or $0.13 per diluted common share, for the fourth quarter 2023. Excluding all non-core income and charges, our adjusted net income (a non-GAA ...